aripiprazole has been researched along with mdl 100907 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Kerpel-Fronius, S; Lóránt, M | 1 |
| Dunlop, J; Kowal, DM; Lou, Z; Nawoschik, SP; Zhang, JY | 1 |
| Duggal, V; Glick, ID; Hodulik, C | 1 |
| Ebrecht, M; Göröcs, T; Gründer, G; Kungel, M; Modell, S | 1 |
| Allers, KA; Bertekap, RL; Burris, KD; Chen, R; Jordan, S; Kikuchi, T; Mistry Kannan, T; Molski, TF; Sharp, T; Stark, AD; Yocca, FD | 1 |
| Kessler, RM | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Franklin, DL; Maguire, GA; Riley, GD; Tran, NL | 1 |
| Sokolski, KN | 1 |
| Azuma, J; Fujiwara, T; Hara, S; Hasunuma, T; Higashi, K; Katano, T; Kitahara, S; Koue, T; Kubo, M; Miyatake, M | 1 |
| Akyol Ardic, U; Ardıc, UA; Ercan, E; Ercan, ES; Uysal, T | 1 |
| De Deyn, PP; Drenth, AF; Kremer, BP; Oude Voshaar, RC; Van Dam, D | 1 |
| Futamura, T; Hashimoto, K; Ishima, T; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Stahl, SM | 1 |
| Blumberger, DM; DiNapoli, EA; Gebara, MA; Karp, JF; Kasckow, J; Lenze, EJ; Mulsant, BH; Reynolds, CF | 1 |
| He, Y; Jiang, H; Jiang, X; Li, J; Liu, Y; Shen, J; Tian, G; Wang, Y; Wang, Z; Wu, C; Xu, M; Yang, F; Ye, B; Zhang, J; Zhao, Q | 1 |
| Kozian, R | 1 |
3 review(s) available for aripiprazole and mdl 100907
| Article | Year |
|---|---|
[A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Metabolic Syndrome; Piperazines; Quinolones; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2004 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
Aripiprazole in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Meta-Analysis as Topic; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine; Serotonin 5-HT2 Receptor Antagonists | 2013 |
3 trial(s) available for aripiprazole and mdl 100907
| Article | Year |
|---|---|
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biotransformation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Genetic Association Studies; Half-Life; Humans; Japan; Male; Metabolic Clearance Rate; Paroxetine; Piperazines; Polymorphism, Genetic; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Young Adult | 2012 |
Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Drug Monitoring; Drug Resistance; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Turkey | 2012 |
Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Topics: Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2018 |
11 other study(ies) available for aripiprazole and mdl 100907
| Article | Year |
|---|---|
Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Calcium; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Female; Humans; Intracellular Space; Olanzapine; Piperazines; Protein Isoforms; Quinolones; Receptor, Serotonin, 5-HT2C; RNA Editing; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Transfection | 2006 |
Aripiprazole as a dopamine partial agonist: positive and negative effects.
Topics: Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Female; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists | 2006 |
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Humans; Limbic System; Mesencephalon; Neural Pathways; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2006 |
Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Interactions; Electrophysiology; Hippocampus; Humans; Male; Neurons; Piperazines; Quinolones; Radioligand Assay; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists | 2007 |
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission | 2007 |
Case report of aripiprazole for persistent developmental stuttering.
Topics: Adult; Anti-Anxiety Agents; Aripiprazole; Humans; Male; Piperazines; Quinolones; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Stuttering | 2008 |
Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Hallucinations; Humans; Loxapine; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2011 |
Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Topics: Animals; Aripiprazole; Boron Compounds; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; HSP90 Heat-Shock Proteins; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Nerve Growth Factor; Neurites; Oxazoles; PC12 Cells; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Agents; Thiophenes | 2015 |
Mechanism of action of brexpiprazole: comparison with aripiprazole.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes | 2016 |
Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine D2 Receptor Antagonists; Humans; Male; Mice, Inbred ICR; Microsomes, Liver; Molecular Structure; Picolinic Acids; Risperidone; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship | 2018 |
[Hypersexuality Induced by Aripiprazole].
Topics: Antipsychotic Agents; Aripiprazole; Germany; Humans; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Sexual Behavior; Sexual Dysfunctions, Psychological | 2020 |